Editorial-Orientierung von MedAPI — kein Bestandteil der Kodieranweisung.
C10 covers primary malignant neoplasms arising in specified oropharyngeal subsites:
- Vallecula
- Anterior (free/lingual) surface of the epiglottis only; the epiglottis proper and other laryngeal portions are classified with laryngeal sites (C32.-)
- Lateral wall of the oropharynx
- Posterior wall of the oropharynx
- Branchial cleft
It also includes residual groupings for overlapping oropharyngeal sites and oropharynx, unspecified; these are not distinct anatomic subsites. Other anatomically oropharyngeal subsites are classified elsewhere — base of tongue and lingual tonsil under C01, soft palate and uvula under C05.-, and tonsil under C09.-. This matters clinically because HPV-mediated oropharyngeal carcinoma most often arises in the tonsil or base of tongue, which fall outside C10.
Common Histologies
- Squamous cell carcinoma, by far the most common histology
- HPV-mediated squamous cell carcinoma, usually associated with high-risk HPV, particularly HPV-16
- HPV-independent squamous cell carcinoma, often associated with tobacco and alcohol exposure
- Less common salivary-type, lymphoepithelial, neuroendocrine, or other carcinomas
A cystic lateral neck mass in an adult should not automatically be considered a primary branchial cleft malignancy. It may represent cervical nodal metastasis from an occult HPV-mediated oropharyngeal carcinoma.
Common Symptoms
- Persistent sore throat (J31.2), dysphagia (R13.10), or odynophagia (R07.0)
- Painless or enlarging cervical mass from nodal involvement (R22.1)
- Referred otalgia (H92.09)
- Globus sensation or voice change (R09.A2) (R09.A2)
- Unexplained weight loss (R63.4)
- Bleeding (R58), trismus (M26.52), or airway symptoms in advanced disease (R06.89)
HPV-mediated tumors may present primarily as a cervical mass despite a small or clinically occult primary lesion.
Diagnosis
Evaluation generally includes a complete head and neck examination, flexible endoscopy, and tissue biopsy. Contrast-enhanced CT or MRI assesses the primary tumor and regional lymph nodes. FDG PET/CT may assist with staging, detection of distant disease, or evaluation for an occult primary. Examination under anesthesia may be appropriate when office assessment is incomplete.
Pathology establishes the histologic diagnosis. For oropharyngeal squamous cell carcinoma, p16 immunohistochemistry is commonly used as a surrogate for transcriptionally active high-risk HPV, with HPV-specific testing used when clinically or pathologically appropriate.
Staging
Staging evaluates primary-tumor extent, cervical nodal disease, and distant metastases. Contemporary AJCC systems use separate staging frameworks for p16-positive HPV-mediated and p16-negative oropharyngeal squamous cell carcinomas because their patterns and prognoses differ. This p16-based stratification applies to oropharyngeal squamous cell carcinoma and is not represented by the C10 code itself.
Imaging and clinical documentation should describe invasion of adjacent structures and the laterality, size, number, and distribution of involved cervical lymph nodes.
Molecular Markers
- p16: Principal surrogate marker used to classify HPV-mediated oropharyngeal squamous cell carcinoma for staging
- High-risk HPV testing: May confirm viral association in appropriate cases
- PD-L1: May inform systemic therapy selection in recurrent or metastatic squamous cell carcinoma
- Broader molecular testing: May be considered in advanced or uncommon tumors when results could affect targeted therapy or clinical-trial eligibility
Common Treatments
Treatment depends on subsite, extent, histology, HPV status, anticipated functional outcomes, and patient factors. Options may include:
- Transoral or open surgical resection, often with neck dissection
- Definitive radiation therapy for selected localized disease
- Concurrent chemoradiation, commonly using a platinum agent, for many locoregionally advanced tumors
- Postoperative radiation or chemoradiation when adverse pathologic features are present
- Immunotherapy, chemotherapy, or other systemic therapy for unresectable recurrent or metastatic disease
- Supportive care addressing nutrition, swallowing, speech, dental health, pain, and treatment-related toxicities
Scope Note
C10 identifies a primary malignant neoplasm by anatomic site within the sites assigned to the oropharynx family and may distinguish certain subsites through its child codes. It does not encode histologic type, p16 or HPV status, tumor grade, TNM stage, nodal involvement, distant metastasis, recurrence, or treatment status. Secondary malignant deposits involving the oropharynx should not be represented as a primary C10 neoplasm; cervical nodal and distant metastases are classified separately when applicable. Base-of-tongue, lingual-tonsil, soft-palate, uvular, tonsillar, and laryngeal primary malignancies belong to their respective site families rather than C10. Tobacco-smoke exposure and alcohol use disorder are frequently documented comorbid factors in this population; consult the official tabular instructions for any accompanying code requirements.